1. Home
  2. VAL vs DFTX Comparison

VAL vs DFTX Comparison

Compare VAL & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valaris Limited

VAL

Valaris Limited

N/A

Current Price

$97.92

Market Cap

6.4B

Sector

Energy

ML Signal

N/A

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$37.25

Market Cap

5.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
VAL
DFTX
Founded
1975
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
5.9B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
VAL
DFTX
Price
$97.92
$37.25
Analyst Decision
Hold
Strong Buy
Analyst Count
9
19
Target Price
$69.00
★ $72.56
AVG Volume (30 Days)
755.4K
★ 1.9M
Earning Date
11-02-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 170.70
N/A
EPS
★ 0.48
N/A
Revenue
★ $2,369,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$12.60
N/A
P/E Ratio
$206.71
★ N/A
Revenue Growth
★ 0.27
N/A
52 Week Low
$48.09
$14.62
52 Week High
$114.12
$49.70

Technical Indicators

Market Signals
Indicator
VAL
DFTX
Relative Strength Index (RSI) 72.38 54.23
Support Level $87.52 $36.11
Resistance Level $104.05 $38.04
Average True Range (ATR) 3.44 1.67
MACD 1.64 0.43
Stochastic Oscillator 90.02 87.21

Price Performance

Historical Comparison
VAL
DFTX

About VAL Valaris Limited

Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: